Explore-CKD
68 evidence topics · 10 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Aim stated in the published report
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual)” (opens the source at this quote in a new tab)
“2023-12-14” (opens the source at this quote in a new tab)
“Primary Completion (Actual)” (opens the source at this quote in a new tab)
“2025-02-27” (opens the source at this quote in a new tab)
“Study Completion (Actual)” (opens the source at this quote in a new tab)
“2025-04-23” (opens the source at this quote in a new tab)
“Results First Posted” (opens the source at this quote in a new tab)
Registered locations
Sites and enrollment period in the published report
Other study identifiers
Study design
Two-period, two-sequence crossover design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “60” |
Blood pressure measurement procedure
Eligibility criteria
Key inclusion and exclusion criteria in the published report
Major inclusion criteria in the ClinicalTrials.gov record
Major exclusion criteria in the ClinicalTrials.gov record
Ages eligible in the ClinicalTrials.gov record
Chronic kidney disease stages described by the sponsor
Treatment
Lorundrostat 25 mg or placebo once daily on background ACEi or ARB and SGLT2 inhibitor
Treatment sequences in the ClinicalTrials.gov record
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Blood pressure control in chronic kidney disease
Clinical relevance of the systolic blood pressure reduction stated by the investigators
Blood pressure reduction as the basis of cardiovascular benefit in FDA labeling guidance
Systolic blood pressure reduction and major cardiovascular events in an individual participant data meta-analysis
Automated office blood pressure measurement
“AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unattended compared with attended automated office blood pressure
Rationale for albuminuria as an exploratory endpoint
Rationale for cystatin C estimated glomerular filtration rate
Safety endpoints and adverse events of special interest
Statistical analysis description
Number of participants (Planned and analyzed)
Participants screened and randomized in the published report
Enrollment in the ClinicalTrials.gov record
Participants analyzed in the posted results
| Analysis | Placebo | Lorundrostat |
|---|---|---|
| Primary outcome, overall number of participants analyzed | “58” | “58” |
| All-cause mortality, affected / at risk (%) | “0/57 (0.00%)” | “0/58 (0.00%)” |
Description of analysis sets
Estimand and handling of missing data for the primary endpoint
Crossover model, sensitivity analysis, and parallel-group analyses
Adverse event reporting in the posted results
Results
Participant disposition
Screening, randomization, and open-label extension enrollment
Baseline characteristics
Demographic and disease characteristics in the published report
Baseline characteristics table (N = 59)
| Characteristic | Value |
|---|---|
| Age, years, mean ± SD | “64.6 ± 10.14” |
| Age 75 years or older, n (%) | “13 (22.0)” |
| Male, n (%) | “41 (69.5)” |
| Female, n (%) | “18 (30.5)” |
| White, n (%) | “39 (66.1)” |
| Black or African American, n (%) | “10 (16.9)” |
| Hispanic or Latino, n (%) | “25 (42.4)” |
| Body mass index, kg/m2, mean ± SD | “33.1 ± 7.10” |
| Seated automated office systolic blood pressure, mm Hg, mean ± SD | “148.9 ± 10.37” |
| Seated automated office diastolic blood pressure, mm Hg, mean ± SD | “82.0 ± 10.49” |
| eGFR (cystatin C), ml/min per 1.73 m2, mean ± SD | “43.0 ± 14.97” |
| eGFR (creatinine), ml/min per 1.73 m2, mean ± SD | “54.6 ± 21.08” |
| UACR (24 hr), mg/g, geometric mean ± SD | “559 ± 2.55” |
| Two or fewer antihypertensive medications, n (%) | “21 (35.6)” |
| Three or more antihypertensive medications, n (%) | “38 (64.4)” |
| β-Blockers, n (%) | “28 (47.5)” |
| Selective calcium-channel blockers with mainly vascular effects, n (%) | “30 (50.8)” |
| Type 2 diabetes mellitus, n (%) | “45 (76.3)” |
| SGLT2i-naive at screening, n (%) | “26 (44.1)” |
Baseline systolic blood pressure by sequence in the posted results
| Group | Seated automated office systolic blood pressure, mmHg, mean (SD) |
|---|---|
| Cohort 1 (lorundrostat, then placebo) | “147.008(9.8704)” |
| Cohort 2 (placebo, then lorundrostat) | “150.802(10.6962)” |
| Total | “148.873(10.3731)” |
Efficacy results
Primary endpoint: change in automated office systolic blood pressure at week 4
Period and carryover effects
Primary outcome in the posted results
| Measure | Placebo | Lorundrostat |
|---|---|---|
| Least squares mean change from baseline, mmHg | “-1.755” | “-9.253” |
| 90% confidence interval | “(-4.966 to 1.455)” | “(-12.453 to -6.053)” |
Albuminuria and proteinuria
Estimated glomerular filtration rate
Topline results table in the sponsor release
| Measure | Placebo | Lorundrostat 25 mg | Placebo-adjusted |
|---|---|---|---|
| Change in systolic BP (mmHg), primary endpoint | “-1.76” | “-9.25” | “-7.5 (p=0.0024)” |
| Change in spot UACR (mg/g) | “-6.60%” | “-30.51%” | “-25.60% (p=0.0015)” |
| Change in eGFR, cystatin C (mL/min/1.73m2) | “-2.20%” | “-6.78%” | “-4.58% (p=0.0362)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events
Overview of treatment-emergent adverse events, n (%) and number of events
| Event | Placebo (n = 57) | Lorundrostat (n = 58) |
|---|---|---|
| TEAEs | “19 (33.3) [36]” | “29 (50.0) [54]” |
| Treatment-related TEAEs | “8 (14.0) [9]” | “16 (27.6) [24]” |
| Serious adverse events | “0 (0.0) [0]” | “2 (3.4) [4]” |
| Adverse events of special interest | “1 (1.8) [1]” | “10 (17.2) [13]” |
| TEAEs leading to discontinuation of the trial drug | “1 (1.8) [1]” | “2 (3.4) [3]” |
| TEAEs leading to dose modification of the trial drug | “4 (7.0) [4]” | “12 (20.7) [15]” |
| Death | “0 (0.0) [0]” | “0 (0.0) [0]” |
Adverse events of special interest and discontinuations
Hyperkalemia
Sodium, kidney function, and cortisol
Serious adverse events in the posted results
| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
|---|---|---|
| Total | “0/57 (0.00%)” | “2/58 (3.45%)” |
| Influenza | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Hyperkalaemia | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Acute kidney injury | “0/57 (0.00%)” | “1/58 (1.72%)” |
Other adverse events in the posted results (frequency threshold 2%)
| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
|---|---|---|
| Total | “18/57 (31.58%)” | “29/58 (50.00%)” |
| Glomerular filtration rate decreased | “2/57 (3.51%)” | “6/58 (10.34%)” |
| Hyperkalaemia | “2/57 (3.51%)” | “9/58 (15.52%)” |
| Hyponatraemia | “3/57 (5.26%)” | “3/58 (5.17%)” |
| Hypotension | “2/57 (3.51%)” | “3/58 (5.17%)” |
| Orthostatic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |
| Diastolic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |
Study limitations
Summary
Explore-CKD was a phase 2, two-period, two-sequence crossover trial with 4-week treatment periods separated by a 4-week washout. The publication reports 59 randomized participants at 42 sites in the United States; the registry lists an enrollment of 60 and 44 locations. One dose, lorundrostat 25 mg once daily, was studied. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure; albuminuria, proteinuria, and eGFR were exploratory endpoints, and no kidney or cardiovascular outcome was assessed. The investigators state that the 4-week treatment period “does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes” and that the findings “will require confirmation in a larger, longer-duration, parallel-arm trial”. Participants with serum potassium above 5.0 mmol/L at screening were excluded, which, with the short treatment duration, the investigators state “could underestimate hyperkalemia risk in routine clinical practice”; hyperkalemia was reported in 9 of 58 participants (15.5%) during lorundrostat treatment and 2 of 57 (3.5%) during placebo. The registry requires stable ACEi or ARB treatment for at least 2 months before screening, and the publication states at least 4 weeks. The trial was designed and funded by Mineralys Therapeutics, three authors are company employees, and no health-related quality of life or patient-reported outcome was reported.